Jury Still Out On Feminine-Hygiene Talc Safety, Except In The Courts
This article was originally published in The Rose Sheet
Executive Summary
Health and scientific authorities have taken various positions on the possible link between perineal talcum-powder use and ovarian cancer, including that the substance is safe as used, is "possibly carcinogenic" and that data is insufficient to allow for a conclusive assessment. Juries in J&J talc trials have been more convinced of the talc-cancer correlation and the firm's negligence in not warning consumers about risks.
You may also be interested in...
J&J Talc Suit Dismissals: Plaintiffs Lack Causation Thread For Proof Quilt
Following two plaintiff victories and hefty damages awards in a Missouri circuit court earlier this year, J&J succeeded last week in having a pair of talc cancer cases dismissed in New Jersey due to plaintiffs’ lack of compelling causation evidence. With more than 1,000 talc suits against J&J still pending, the relative weight of expert testimonies – and venue – likely will continue to be significant factors in how they play out.
J&J Slapped With Another Talc Cancer Verdict As More Claimants Line Up
J&J is ordered to pay $55m in damages to a woman who attributes her ovarian cancer to prolonged perineal use of the company's talc-based powders. The decision comes less than three months after a $72m finding against J&J in a similar case tried in the same St. Louis court, but this one may bode more ominously for the firm's prospects in a long line of related cases to come, plaintiff's counsel suggests.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.